Finance

Lists
PGEN:NASDAQ
Precigen Inc
7,48 USD
+1,63%
(+0,12) 1D
15-окт., 11:35:45 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PGEN...
Open
7,31 USD
High
7,55 USD
Low
7,20 USD
Mkt. cap
2,68 млд
Avg. vol.
4,72 млн
Volume
1,48 млн
52-wk high
8,98 USD
52-wk low
3,04 USD
EPS
-1,10 USD
Beta
0,92
Shares outstanding
358,04 млн
No. of employees
160
Open
7,31 USD
High
7,55 USD
Low
7,20 USD
Mkt. cap
2,68 млд
Avg. vol.
4,72 млн
Volume
1,48 млн
52-wk high
8,98 USD
52-wk low
3,04 USD
EPS
-1,10 USD
Beta
0,92
Shares outstanding
358,04 млн
No. of employees
160
News stories
From web sources and news partners
Profile
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Wikipedia
About Precigen Inc
CEOHelen Sabzevari
Employees160
Founded1998-ж., 21-май
Headquarters-
Sector-
Websiteprecigen.com
Analyst ratings
Based on 2 analysts giving stock ratings to PGEN in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for PGEN in the last 3 months.
Highest
Current 7,48 USD
18,00 USD (+140,80%)
Average
15,00 USD (+100,67%)
Lowest
12,00 USD (+60,54%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
18,00 USD
+140,8%
10/01/2026
Yuan Zhi
B. Riley Securities
Buy
Initiated
12,00 USD
+60,5%
09/25/2026
Jason Butler
Citizens JMP
Buy
Maintained
11,00 USD
+47,2%
05/14/2026
Last report
2026-ж., 4-авг.
Fiscal period
Q2 2026
- /
Revenue / Est. (USD)
54,98 млн / 27,83 млн
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
2,92 млн
4,56 млн
23,25 млн
54,98 млн
Cost of goods sold
13,41 млн
8,59 млн
8,20 млн
10,09 млн
Cost of revenue
13,41 млн
8,59 млн
8,20 млн
10,09 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23,99 млн
17,64 млн
21,05 млн
22,25 млн
Operating expense
23,99 млн
17,64 млн
21,05 млн
22,25 млн
Total operating expenses
37,40 млн
26,23 млн
29,25 млн
32,34 млн
Operating income
-34,48 млн
-21,67 млн
-5,99 млн
22,64 млн
Other non operating income
-111,50 млн
60,00 миң
290,00 миң
16,00 миң
EBT including unusual items
-146,34 млн
-23,50 млн
-7,93 млн
20,07 млн
EBT excluding unusual items
-146,34 млн
-23,50 млн
-7,93 млн
20,07 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-146,34 млн
-23,50 млн
-7,93 млн
20,07 млн
Net profit margin
-5 008,35%
-514,85%
-34,10%
36,51%
Earnings per share
-
-
-
-
Interest and investment income
534,00 миң
1,07 млн
683,00 миң
366,00 миң
Interest expense
-902,00 миң
-2,96 млн
-2,91 млн
-2,95 млн
Net interest expenses
-368,00 миң
-1,90 млн
-2,22 млн
-2,59 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,68 млн
-20,53 млн
-4,90 млн
23,74 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору